It was confirmed that Gpr35 may prevent PD by modulating neuroinflammation and gut microbiota and metabolite composition, specifically through enriching Lactobacillus, and substantially regulating tyrosine metabolism, neuroactive ligand–receptor interaction, and tryptophan metabolism pathways, thereby inhibiting the progression of PD. This evidence concerns the gene GPR35 and Parkinson disease.